SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
STEM_758_sm_supplFigure1.pdf115KSupplemental Figure 1. Summary of gene expression changes in the FGF signaling pathway during hESC neural differentiation. Reported changes are ratios of expression values of samples from day 6 or day 10 compared to day 0 (ESC stage). Yellow boxes indicate no change in expression from ESC stage to day 6 or day 10. Red boxes indicate an increase in expression level and green boxes indicate downregulation.
STEM_758_sm_supplFigure2.tif1851KSupplemental Figure 2. hESCs (d0) and differentiating cells at day 2 (d2), d4 , d6, d8, and d10 were subjected to immunoblotting assay with Ab-PAR, -PARP-1, -ERK, -p-ERK as indicated.
STEM_758_sm_supplFigure3.pdf302KSupplemental Figure 3. hESC lines expressing PARP-1-shRNA and control shRNA. GFP was used as a viral marker.
STEM_758_sm_supplFigure4.pdf79KSupplemental Figure 4. PARP-1 knockdown inhibits neural differentiation of hESCs. The expression of PAX6 and SOX2 in PARP-1-knockdown cell lines at day10 of differentiation was assessed by flowcytometry. The value of each cell line was normalized to its own IgG control. The mean ± S.E. of relative value of PAX6 or SOX2 expressing cells from three independent experiments are shown after normalization to that of control RNAi. *, P<0.05, **, P>0.05 in comparison with the value from control cell line.
STEM_758_sm_supplFigure5.pdf120KSupplemental Figure 5. Neural differentiating PARP-1 knockdown (#3) or control cells at day10 were fixed and subjected to immunostaining with Ab- PARP-1, PAX6 or SOX2 as indicated. All cells express GFP, a viral marker.
STEM_758_sm_supplFigure6.pdf74KSupplemental Figure 6. Lysates from cell lines expressing PARP-1-shRNA and control shRNA at differentiating day 10 (d10) were subjected to immunoblotting with Abs against other lineage markers, Cytokeratin (epidermal), Brachiury (early mesodermal) and SOX17 (endodermal) as indicated.
STEM_758_sm_supplTable1.pdf230KSupplementary Table 1. Primer list

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.